Sagimet Biosciences Highlights Denifanstat MASH Data, Combo Plans at Oppenheimer Healthcare Conf. [Yahoo! Finance]
Sagimet Biosciences Inc. - Series A (SGMT)
Company Research
Source: Yahoo! Finance
significance—showing fibrosis improvement without worsening MASH and MASH resolution without worsening fibrosis—while digital pathology supported results and patients on drug were about half as likely to progress to cirrhosis. Sagimet is advancing a combination program with resmetirom for qF4 cirrhotic patients after a ~40-subject Phase 1 PK/DDI study showed the combo was well tolerated; planned Phase 2 will test multiple doses versus components and placebo with assessments at 52 and 96 weeks. In acne, China partner Ascletis completed a Phase 3 of 50 mg denifanstat that met endpoints and the NMPA accepted the NDA (Dec 2025), making Sagimet eligible for up to $122 million in milestones plus royalties, and the company is also moving next-generation FASN inhibitor TVB-3567 into Phase 1. Interested in Sagimet Biosciences Inc.? Here are five stocks we like better. Sagimet Biosciences (NASDAQ:SGMT) used an investor discussion at Oppenheimer's 36th Annual Healthcare Life Sciences Con
Show less
Read more
Impact Snapshot
Event Time:
SGMT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SGMT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SGMT alerts
High impacting Sagimet Biosciences Inc. - Series A news events
Weekly update
A roundup of the hottest topics
SGMT
News
- Sagimet Biosciences Inc. (SGMT) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript [Seeking Alpha]Seeking Alpha
- Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
- Sagimet Biosciences Announces Participation in Three Upcoming Investor ConferencesGlobeNewswire
- Sagimet Biosciences Announces Participation in Two Upcoming Investor ConferencesGlobeNewswire
- Sagimet Biosciences (NASDAQ:SGMT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $29.00 price target on the stock.MarketBeat
SGMT
Earnings
- 11/13/25 - Beat
SGMT
Sec Filings
- 2/20/26 - Form 4
- 2/20/26 - Form 4
- 2/20/26 - Form 4
- SGMT's page on the SEC website